MEDI-534

BIOLOGICAL3 trials

Sponsors

MedImmune LLC

Conditions

HealthyParainfluenza InfectionsParainfluenza Virus 3, HumanRespiratory Syncytial Virus InfectionsRespiratory Viral Infections

Phase 1

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

CompletedNCT00345670

MedImmune LLCHealthy

Start: 2006-06-30End: 2007-05-31Target: 120Updated: 2008-09-03

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

CompletedNCT00493285

MedImmune LLCParainfluenza Virus 3, Human, Respiratory Syncytial Virus Infections, Respiratory Viral Infections

Start: 2007-07-31End: 2010-04-30Updated: 2012-07-19

Unknown Phase

Study to Evaluate MEDI-534 in Healthy Adults

CompletedNCT00111878

MedImmune LLCParainfluenza Infections, Respiratory Syncytial Virus Infections

Start: 2005-04-30End: 2005-12-31Target: 120Updated: 2007-07-03